Minoryx Launches Phase 2/3 Trial for AMN Drug

Minoryx Therapeutics, the Spanish pharmaceutical company based in Barcelona and headed up by Mark Martinell, is preparing to launch Phase II/III trial for their drug MIN-102, which could potentially alleviate AMN symptoms. To support the effort, they have recruited ALD Life friends and renowned ALD/AMN specialists Professor Patrick Aubourg, Dr Florian Eichler,

Read More

Newsletter Sign-up

News, events, and more...